BioNano Genomics, Inc. (BNGO) Reports Q3 Revs of $2.2M

Go back to BioNano Genomics, Inc. (BNGO) Reports Q3 Revs of $2.2M

Bionano Genomics Reports Third Quarter 2020 Financial Results and Provides Business Update

November 12, 2020 4:01 PM EST

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business, today reported its financial results for the third quarter ended September 30, 2020 and provided a business update.

We believe key events this quarter have set us up for continued growth and success, said... More